About Our Company
OUR SERVICES
MKTXS has the tools to help pharmaceutical/biotechnology companies build effective strategies to resolve key market access concerns and enhance product value
Evidence Generation
Strategic market access
GVDs
Contracting& payer strategy
Real World Evidence
Value Message Testing
Pricing & reimbursement strategy
Launch sequencing assessment
Analog Case Studies & Analysis
Advisory Boards / Panels (PRISM)
Proprietary Technologies
Systematic / Targeted Literature Reviews
MKTXS provides integrated offerings across all stages of the product life-cycle to optimize price and access upon launch
Development Phase
Challenges
MKTXS Offerings
Pre-clinical - Phase I
Opportunity Assessment
- Disease/treatment landscape assessments
- Analog case studies
- Payer environment understanding
- Clinical outcomes evaluation
- Value driver ranking
Phase II - Phase III
Evidence / Trial Design
Generation
- Epidemiology and target patient population
- Value gap/driver analysis
- Qualitative pricing insights
- Trial design optimization
- HTA evaluation preparation
- PRO requirements
- Efficacy/safety performance
- Economic value optimization
Phase III - Launch
Value Proposition Development & Validation
- Launch sequencing and indication anticipation
- Launch price strategy
- Price optimization
- IRP analysis
- Competitive landscape
- Payer negotiation strategy/training
- Stakeholder-specific value message development and testing
- Core budget impact and cost-effectiveness model development
Phase IV – Patent Expiration
Market Shaping / Revenue Optimization
- Real-world evidence generation
- Utilization
- Safety and HRQoL
- Comparative effectiveness
- Global economic models
- Market share optimization strategies upon patent expiration/generic entry
- Lifecycle Planning
- Differentiation among increased competition
Sandip Shah
President & CEO
The Founder and CEO of Market Access Solutions (MKTXS), Sandip Shah, is a seasoned and experienced pricing strategist with 30+ years of experience in the healthcare sector, including 23 years in Global PRMA.
Sandip is now focused on providing global strategic guidance in pricing and reimbursement at all phases of pharmaceutical and medical/surgical product development through to customer segment contracting and has led countless initiatives managing and providing global market access strategies to Fortune 500 clients in numerous therapeutic areas for the last two decades.
Prior to starting the company, Sandip was with the Johnson and Johnson family of companies from 1994-2004, where he developed optimal Price and Reimbursement strategies for the pharmaceutical, medical and surgical sectors and worked with local operating companies globally to implement recommendations. Before his time at Johnson and Johnson, Sandip oversaw inline product pricing and contracting at Glaxo Pharmaceuticals. Sandip has also managed sales/marketing services departments including compensation and forecasting.
He holds an MBA from Duke and a Bachelor’s in Chemical Engineering from Purdue University.
Recognized authority in Global Pricing and Market Access for healthcare technology innovations
- Strategic Pricing
- Value Optimizing Asset Development Strategy
- Global Price, Reimbursement, and Market Access (PRMA) Systems, including HTAs
- Competitive Assessment
- Life-Cycle Value Optimization
- Opportunity Assessments
- Rare / Orphan Disease Expertise
- Executive and C-suite Communications